Recommendations on the Clinical Use of Bendamustine in Lymphoproliferative Syndromes and Multiple Myeloma

This is a clinical practice guideline on the clinical use of bendamustine for the management of patients with hematological cancers. The guideline specifically addresses diseases in which bendamustine is widely used and approved, including indolent non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL), and multiple myeloma (MM). Dose and treatment regimens for different clinical indications, the management of toxicity, and supportive therapy are discussed.